Ongoing Treatment Challenges in Chronic Lymphocytic Leukemia (CLL)
0 SAR
Checkout
Overview
- Objectives:
- Highlight the ongoing treatment challenges faced by patients with CLL.
- Increase awareness of unmet needs across the CLL treatment journey.
- Discuss considerations for treatment sequencing and management in relapsed/refractory CLL.
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
CMAT-17532
This Class for
- Clinical Pharmacy
- Pharmacy
- Physician
- Resident / Fellow
Related Classes
- CLL‑321 Manuscript Insights: Thought Leader Perspective on Pirtobrutinib with Prof. Paolo Ghia
- Identifying node-positive, high-risk EBC patients to optimize treatment outcomes with Verzenio